tbuckley/cabot-search huggingface dataset:
Chronic hepatitis C virus infection established and maintained in chimpanzees independent of dendritic cell impairment
Authors: Christine Rollier, Joost A.R. Drexhage, Babs E. Verstrepen, Ernst J. Verschoor, Ronald E. Bontrop, Gerrit Koopman, Jonathan L. Heeney
Journal: Hepatology (2003)

Chronic hepatitis C virus (HCV) infection in humans is associated with an impairment of dendritic cells (DC). It has been hypothesized that impairment of DC function may be a central mechanism facilitating the establishment of a chronic carrier state. However, the majority of patients studied with DC impairment to date have been identified and, thus, inadvertently selected because of clinical manifestations leading to their diagnosis, which may have been many years following actual infection. We set out to determine whether impaired DC function occurred in the earlier asymptomatic phase of infection and turned to a well–defined cohort of HCV–infected chimpanzees in which the specific date of infection and the nature of the inoculum were well characterized. Results revealed that, in contrast to the observations in human subjects with advanced clinical hepatitis, there was neither impairment of the allostimulatory capacity of monocyte–derived DC from HCV chronic carriers nor impairment of the maturation process. Decreased allostimulatory capacity was only detected in 2 animals and, interestingly, in those that possessed the highest viral loads. Nevertheless, HCV sequences were undetectable in any of the DC derived from HCV–infected chimpanzees. In conclusion, these findings suggest that the mechanisms of establishing persistent HCV infection are separate and independent from those responsible for impaired DC function. Indeed, the maturation and allostimulatory impairment, as described in patient studies, are not necessary prerequisites but rather possible consequences of persistent and active HCV infection associated with disease progression. (Hepatology 2003;38:851-858).
The subsequent risk of internal cancer with Bowen's disease. A population-based study
Authors: C. G. Chute
Journal: JAMA (1991)

<h3>Objective.</h3> —To address the subsequent risk of internal cancer in a population-based cohort of patients with Bowen's disease. <h3>Design.</h3> —Incident cases of skin cancers other than malignant melanoma occurring in a defined population were classified as basal cell carcinoma, squamous cell carcinoma, or Bowen's disease. Through medical records, all patients were followed up for the development of subsequent internal cancer until they died, moved from Rochester, Minn, or January 1, 1986, whichever came first. Incidence rates of skin cancer and subsequent cancer were computed; the subsequent rate of internal cancer was compared with that prevailing in the community. <h3>Patients.</h3> —Enrolled were all permanent residents in the population base of Rochester, Minn, who developed basal cell carcinoma (n = 657), squamous cell carcinoma (n = 169), or Bowen's disease (n = 71) on the basis of pathologic examination and clinical presentation from 1976 through 1984. <h3>Main Outcome Measure.</h3> —The relative risk of subsequent internal cancer among patients with Bowen's disease compared with that of the population base from which they arose was 1.1 (95% confidence limits, 0.5,1.6). <h3>Results.</h3> —Annual incidence rates, adjusted to the 1980 US white population, were 14.9 per 100 000 for Bowen's disease, 38.8 for squamous cell carcinoma, and 146 for basal cell carcinoma. The estimated relative risk for subsequent cancer was 0.9 (95% confidence limits, 0.5, 1.6) among patients with squamous cell carcinoma and 1.0 (95% confidence limits, 0.7, 1.3) for patients with basal cell carcinoma. These risks were not significantly different for various durations of follow-up or for sun-exposed vs sun-protected sites. <h3>Conclusions.</h3> —We find no evidence in these population-based cohort data of an increased risk of subsequent internal cancer associated with Bowen's disease or other forms of nonmelanomatous skin cancer. (<i>JAMA</i>. 1991;266:816-819)
Taps
Authors: Laurie L. Brown
Journal: JAMA (1990)

Her first baby died shortly after birth. Her second was stillborn. She desperately wanted a child. Now the time of birth of her third child was near, and she was scheduled for a cesarean section. I was the anesthesiologist. It was not long after World War II—only a few short years—just enough time for our country to have been involved in another three-year war, commonly known as the Korean conflict. I guess "conflict" doesn't sound as bad as "war," but the thousands who died during that conflict are just as dead as any of those killed in the world's "greatest" wars. Any war is hell on earth! I had finished college and was now in medicine, so I escaped return to active service and another trip to foreign lands. After the conflict was over, our city remained one of military might. Its uniformed men and women, and its planes and
Value of chemoprophylaxis and chemotherapy in early chronic bronchitis. A report to the Medical Research Council by their working party on trials of chemotherapy in early chronic bronchitis.
Journal: BMJ (1966)

In order to discover whether progression of chronic bronchitis may be delayed by control of recurrent infection it was'decided in 1957 to carry out a controlled double-blind trial of chemo- prophylaxis and chemotherapy on cases of chronic bronchitis with a history of recurrent infection but with mild disability, and to observe the associated changes of respiratory function.To obtain the necessary numbers of subjects chest physicians in various parts of the country were invited to participate, and they agreed upon a plan (approved by the then Antibiotics Clinical Trials Committee of the Medical Research Council).This report is concerned with the frequency and severity of ill- nesses and changes in ventilatory capacity during the first five years of the trial. Methods Recruitment of CasesThe trial was carried out on men aged 40-59 in full employment who had a productive cough (grade 2, Medical Research Council, 1960) and who had had at least two chest illnesses with increased phlegm, and a total absence from work of at least three weeks during the previous three years.The forced expiratory volume in one second (F.E.V) had to be over 1.4 litres.Men were excluded if they suffered from any other disabling condition.Considerable difficulty was encountered in recruitment.Most men attending chest clinics for chronic bronchitis have F.E.V. levels below 1.4 litres.Most men with high values of F.E.V. had infrequent illnesses, while those with recurrent ill- nesses usually had low values, and this was the most common reason for rejection of otherwise suitable patients.It was hoped that each of the 13 participating physicians would obtain 60 cases within the first year, but only one clinic reached this number despite recruitment over two years (see Table I).There is evidence that different clinics recruited rather different types of subject. Therapeutic RegimenOxytetracycline was chosen for prophylaxis, initially in a dose of 0.5 g. once daily in the morning from mid-September to mid-April each year.It was hoped that if this small and economic dose proved effective it might be more practicable on a national scale than a larger, more expensive dose.Boxes of
Current Comment
Journal: JAMA (1935)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Anleitung zur frühzeitigen Erkennung der Krebskrankheit: Im Auftrage des Landesausschusses zur Erforschung und Bekämpfung der Krebskrankheit in Sachsen.
Journal: JAMA (1933)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue
THE INTESTINAL ORIGIN OF PULMONARY TUBERCULOSIS.
Journal: JAMA (1906)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Cyclamate Sweeteners
Authors: Robert H. Kellen
Journal: JAMA (1977)

<h3>To the Editor.—</h3> The article "Cyclamate Sweeteners" (236:1987, 1976) presented a fairly accurate summary of the US history of the cyclamate controversy. However, it failed to point out that Food and Drug Administration Commissioner Alexander M. Schmidt's decision last year to continue the ban on cyclamate was strictly arbitrary. It further omitted the fact that cyclamate is currently in use in many nations throughout the world and has been exposed to exhaustive tests and data scrutiny and been found safe by scientists from many governments and organizations, including the World Health Organization, Australia, Canada, Finland, West Germany and Switzerland. The Commissioner chose to disregard the scientific evidence and to abandon the well-established basis for the evaluation of safety applied to other foods and food additives in making his decision. I believe, based on the overwhelming scientific evidence supporting the safety of cyclamate and the undue hardship the Commissioner's decision has
Diagnostic Evaluation of Elderly Patients with Mild Memory Problems
Authors: Jason Karlawish, Christopher M. Clark
Journal: Annals of Internal Medicine (2004)

Letters6 January 2004Diagnostic Evaluation of Elderly Patients with Mild Memory ProblemsJason Karlawish, MD and Christopher M. Clark, MDJason Karlawish, MDFrom University of Pennsylvania; Philadelphia, PA 19104.Search for more papers by this author and Christopher M. Clark, MDFrom University of Pennsylvania; Philadelphia, PA 19104.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-140-1-200401060-00034 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail IN RESPONSE:To apply the label of “neurodegenerative dementia” to a patient, a clinician needs to show declines in a person's cognition that explain changes in the person's ability to perform usual and everyday activities, such as managing a checkbook or preparing a cup of tea (1). The point of showing deficits in at least 2 domains of cognition is to reduce the chance that the problem could be due to a single brain lesion rather than diffuse neurodegenerative pathology. As elegant as these criteria are in linking disease with a set of signs and symptoms, several challenges hinder clinicians ...References1. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology. 1984;34:939-44. [PMID: 6610841] CrossrefMedlineGoogle Scholar2. Karlawish JH. The search for a coherent language: the science and politics of drug testing and approval.. In: Kapp MB, eds. Ethics, Law and Aging Review. vol 8. New York: Springer; 2002:39-56. Google Scholar Author, Article, and Disclosure InformationAuthors: Jason Karlawish, MD; Christopher M. Clark, MDAffiliations: From University of Pennsylvania; Philadelphia, PA 19104. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoAlzheimer Disease: Current Concepts and Emerging Diagnostic and Therapeutic Strategies Christopher M. Clark and Jason H.T. Karlawish Alzheimer Disease: Current Concepts and Emerging Diagnostic and Therapeutic Strategies Thomas E. Finucane Metrics 6 January 2004Volume 140, Issue 1Page: 72KeywordsClinical trialsCognitionDementiaHemoglobinHypertensionLesionsMemoryMini mental state examinationSigns and symptomsTea ePublished: 6 January 2004 Issue Published: 6 January 2004 Copyright & PermissionsCopyright © 2004 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
CORPUS LUTEUM EXTRACT IN THE TREATMENT OF THE VOMITING OF PREGNANCY
Journal: JAMA (1922)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Hemoglobin-Based Blood Substitutes and Risk of Myocardial Infarction and Death
Authors: Peter E. Keipert
Journal: JAMA (2008)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Manual of Applied Nutrition, The Johns Hopkins Hospital
Journal: JAMA (1941)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Corrigendum
Journal: BMJ (1940)

sick and wounded troops in civilian hospitals.and troops are sent to out-patient clinics for an expert consultant's opinion.This consulttation, for which the ordinary fee in private practice is three guineas, costs the Government 6d.For an in-patient soldier the State pays Is. 6d. per night to be shared among the honorary medical staff.And when all the expert work is done the soldier, quite rightly, will be moved to con- valesce in a safer area at the same rate of payment.More- over.if at any time there are no sick or wounded military sick in the hospital the staff are expected to remain available, but no retaining fee of any kind is paid.Contrast this with the cost of maintaining a fully equipped military base hospital, with a staff of full-time, paid medical officers even if the hospital is empty.The financial saving is so great that any administrative inefficiency can be overlooked.The profes-
Prevalence and Impact of Arthritis Among Women—United States, 1989-1991
Journal: JAMA (1995)

Arthritis and other rheumatic conditions are among the most prevalent chronic conditions in the United States, affecting approximately 38 million persons (1). The self-reported prevalence of arthritis is greater among women than among men, and for women aged > 45 years, arthritis is the leading cause of activity limitation (1,2). This report uses data from the National Health Interview Survey (NHIS) to provide estimates of the prevalence and impact of arthritis among women aged > or = 15 years during 1989-1991, compares the prevalence estimates of arthritis to other chronic conditions affecting women during 1989-1991, and projects the prevalence of arthritis among women in 2020.
THE SYMPTOMATOLOGY OF OCCLUSION OF THE MESENTERIC ARTERY.
Journal: JAMA (1901)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Error in Patient Page
Authors: Kevin Fain, G Alexander
Journal: JAMA (2013)

It is reassuring that 99% of studies required under the FDAAA are proceeding according to schedule.Although our report reflects this, nearly three-fourths of these studies (271/ 387) have not yet been initiated.We hope that regulatory changes facilitated by the FDAAA will help the Agency to keep these newer studies on track.Kashoki and colleagues also emphasize that studies that are pending are not technically behind schedule, even though the study has not yet started.We understand this point but note that the Institute of Medicine expressed concern with the numbers of studies not yet started (in the 2005 Federal Register notice) and the lack of agency authority to enforce implementation. 4 We believe trends in these studies not yet started are informative about overall implementation of the FDAAA.The FDA has made commendable efforts clearing the initial backlog of studies that preceded, and indeed motivated, parts of the FDAAA that gave the Agency greater ability for regulatory enforcement.The FDA's efforts will remain important for managing a large number of complex investigations that are essential in determining the real-world safety and effectiveness of regulated products.We hope our analysis can provide a helpful foundation for the continued assessment of this undertaking.
New Consultant Contract
Authors: L. J. Temple, H. Alty, B. J. Bickford, J. Campbell, W. H. R. Cook, J. Davidson, G. Duncan, A. M. Florence, J. P. Heron, G. Honey, T. MacLeod, R. B. McConnell, J. B. Meade, J. Moroney, I. M. Morrison, E. Parry, J. C. Richardson, L. B. Scott, J. Shepherd, J. K. B. Waddington, G. P. Walker
Journal: BMJ (1972)